Search Results
Jan 28, 2026, 08:30 ET Dominari Holdings Issues Letter to Shareholders
all of the principal invested. You can check the background of Dominari Securities and its registered investment professionals and review its SEC Form CRS on FINRA's BrokerCheck site at
More news about: Dominari Holdings Inc.
Jan 26, 2026, 19:00 ET Innovent Announces IBI3003 (GPRC5D/BCMA/CD3 Trispecific Antibody) Receives Fast Track Designation from the U.S. FDA for Relapsed or Refractory Multiple Myeloma
next generation sequencing, with a threshold of 10-5, performed at a central laboratory.All cases of cytokine release syndrome (CRS) were Grade 1-2, with only 2 cases of Grade 1-2 immune effector cell-associated neurotoxicity syndrome (ICANS) reported. Most treatment-emergent adverse
More news about: Innovent Biologics
Jan 26, 2026, 10:16 ET Breaking Barriers: How 2026's Top Clinical Leaders Are Disrupting Chronic Disease Markets
at month 6, while DL2 decreased 65% at month 3 and 78% at month 6. Clinical SLEDAI-2K of 0 was achieved in 5 out of 10 patients with no Grade >2 CRS, ICANS, or GVHD reported.Ardelyx (NASDAQ: ARDX)
More news about: Equity Insider
Jan 16, 2026, 13:43 ET AbbVie Announces Topline Results for Epcoritamab (DuoBody® CD3xCD20) from Phase 3 EPCORE® DLBCL-1 Trial in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
serious side effects, including:Cytokine release syndrome (CRS), which is common during treatment with EPKINLY and can be serious or lead to death. To help reduce your risk of CRS, you will receive EPKINLY on a step-up dosing schedule (when you receive 2 or 3 smaller
More news about: AbbVie
Jan 15, 2026, 20:00 ET Antengene Presents at JPM: Strong Clinical Data Update and Strategic Focus on Next-Generation ADCs and TCEs
for low-expressing targets, steric hindrance masking, and proprietary CD3 sequences with fast on/off kinetics to minimize cytokine release syndrome (CRS) and enhance efficacy. These characteristics support the platform's broad applicability across autoimmune diseases, solid tumors and hematological
More news about: Antengene Corporation Limited
Jan 15, 2026, 06:00 ET Cowbell Appoints Simon Hughes as Chief Commercial Officer
in commercial and specialty lines, including cyber, technology errors and omissions, and management liability. Through Cowbell Resiliency Services (CRS)—an independent cybersecurity advisory arm—policyholders gain access to Digital Forensics and Incident Response (DFIR) services as well as proactive solutions
More news about: Cowbell Cyber, Inc.
Jan 14, 2026, 16:30 ET TECVAYLI® monotherapy demonstrates superior progression-free and overall survival versus standard of care as early as first relapse in patients with multiple myeloma predominantly refractory to anti-CD38 therapy and lenalidomide
release syndrome (CRS), including life-threatening or fatal reactions. In the clinical trial, CRS occurred in 72% of patients who received TECVAYLI® at the recommended dose, with Grade 1 CRS occurring in 50% of patients, Grade 2 in 21%, and Grade 3 in 0.6%. Recurrent CRS occurred in 33% of
More news about: Johnson & Johnson
Jan 14, 2026, 10:00 ET McWhinney Rebrands as Realberry, Advancing a More Accessible Real Estate Investment Platform
any particular security, strategy, or investment.Securities offered through North Capital Private Securities, Member FINRA/SIPC. Its Form CRS may be found
More news about: Realberry
Jan 13, 2026, 03:26 ET Immunofoco Presents Phase I/IIa Data of IMC002 at ASCO GI 2026, Highlighting a Durable Complete Response Beyond One Year and a 66.7% ORR in Advanced GC/GEJ
profile, with no dose-limiting toxicities observed during the dose-escalation phase. Cytokine release syndrome (CRS) occurred in all patients but was limited to Grade 1 or 2, and no Grade ≥3 CRS, ICANS, or treatment-related deaths were reported.In evaluable patients, IMC002 achieved an objective
More news about: Immunofoco Biotechnology
Jan 09, 2026, 16:00 ET Phanes Therapeutics Announces Positive Phase 2 Results of Spevatamig (PT886) in Combination with Chemotherapy in Frontline (1L) Treatment of Metastatic PDAC at ASCO GI 2026
spevatamig + GnP still maturing. Of note: Spevatamig has demonstrated a favorable safety profile. In monotherapy, no CRS or DLTs were observed. The maximum tolerated dose (MTD) has not been reached in either the monotherapy or combination therapy setting. No Grade ≥ 3 treatment-emergent
More news about: Phanes Therapeutics, Inc.
Jan 07, 2026, 08:00 ET CRS, a Reverence Capital Partners Portfolio Company, Announces Sale to Ridgemont Equity Partners
capabilities to CRS. Under Reverence Capital's ownership, CRS also successfully launched its Managed Repair Program in 2024, a new business line that facilitates home repair and restoration services for insurance carriers and their policyholders."Under Reverence Capital's ownership, CRS more than doubled
More news about: Reverence Capital Partners
Jan 06, 2026, 09:30 ET Lung Cancer Research Foundation Announces Additional 2025 Scientific Research Grant Awards
how to predict which patients will benefit from this treatment and who is at higher risk for CRS. The study has two main aims: 1. Predicting who responds to the drug and 2. Identifying who is at risk for CRS in order to develop a new framework for personalizing treatment, making it more effective and
More news about: Lung Cancer Research Foundation
Jan 05, 2026, 06:00 ET Cowbell Announces Next Cycle of Growth, Profitability, and Global Expansion; Appoints John Botros as Chief Financial Officer
in commercial and specialty lines, including cyber, technology errors and omissions, and management liability. Through Cowbell Resiliency Services (CRS)—an independent cybersecurity advisory arm—policyholders gain access to Digital Forensics and Incident Response (DFIR) services as well as proactive solutions,
More news about: Cowbell
Dec 28, 2025, 19:10 ET CARsgen Submits Dual IND Applications for Allogeneic BCMA CAR-T Product CT0596
lymphodepletion), 1 achieved very good partial response (VGPR), and 2 achieved PR. Four patients experienced Grade 1 cytokine release syndrome (CRS), with no Grade 2 or higher CRS observed. No immune effector cell-associated neurotoxicity syndrome (ICANS), GvHD, dose-limiting toxicities, treatment discontinuations,
More news about: CARsgen Therapeutics
Dec 19, 2025, 07:44 ET Immunotherapies Replacing Chemotherapy as Blood Cancer Market to Hit $13B by 2030
with high-risk relapse and patients with primary CNS relapse. Consistent with our experience in the adult population, data show low rates of severe CRS and ICANS."Autolus also presented post-hoc analyses from the FELIX pivotal trial demonstrating that CAR T-cell persistence at three months
More news about: USA News Group
Dec 16, 2025, 20:00 ET Antengene Expands XPOVIO® Indications in Malaysia with Approval in Diffuse Large B-cell Lymphoma
for low-expressing targets, steric hindrance masking, and proprietary CD3 sequences with fast on/off kinetics to minimize cytokine release syndrome (CRS) and enhance efficacy. These characteristics support the platform's broad applicability across autoimmune disease, solid tumors and hematological malignancies
More news about: Antengene Corporation Limited
Dec 12, 2025, 17:45 ET Dominari Holdings Announces Change of Record Date and Payment Date for $10 Million Cash Dividend
all of the principal invested. You can check the background of Dominari Securities and its registered investment professionals and review its SEC Form CRS on FINRA's BrokerCheck site at
More news about: Dominari Holdings Inc.
Dec 12, 2025, 09:00 ET Roivios Reports Promising Results from First-in-Human Trial of JuxtaFlow® Renal Assist Device
novel therapy has shown potential to improve outcomes for patients with acute decompensated heart failure and diuretic-resistant cardiorenal syndrome (CRS).
More news about: Roivios, ltd
Dec 11, 2025, 07:00 ET Dominari Holdings Announces $10 Million Cash Dividend
all of the principal invested. You can check the background of Dominari Securities and its registered investment professionals and review its SEC Form CRS on FINRA's BrokerCheck site at
More news about: Dominari Holdings Inc.
Dec 09, 2025, 11:15 ET Airiver Medical Secures IDE Approval from the FDA for Pivotal Clinical Study of the Airiver Drug Coated Balloon for Patients with Chronic Rhinosinusitis
officer for Airiver Medical.CRS is defined as long-term (present for a minimum of three months despite intervention) symptomatic inflammation of the nose and paranasal sinuses. CRS is one of the most common chronic medical conditions in the world. For many CRS sufferers, medication alone is not
More news about: Airiver Medical
Dec 09, 2025, 08:44 ET Mamba Brand CEO Claims FDA & DEA Lack Funding and Law Enforcement Capacity to Enforce New Hemp Ban
funding, staffing, and federal infrastructure, according to a newly released congressional analysis. The Congressional Research Service (CRS)—the nonpartisan investigative office that advises U.S. lawmakers—issued a report warning that both the Food and Drug Administration (FDA) and
More news about: The Mamba Brand LLC
Dec 09, 2025, 07:44 ET Unprecedented results from the Phase 3 MajesTEC-3 study support TECVAYLI® plus DARZALEX FASPRO® as a potential standard of care as early as second line for patients with relapsed/refractory multiple myeloma
release syndrome (CRS), including life-threatening or fatal reactions. In the clinical trial, CRS occurred in 72% of patients who received TECVAYLI® at the recommended dose, with Grade 1 CRS occurring in 50% of patients, Grade 2 in 21%, and Grade 3 in 0.6%. Recurrent CRS occurred in 33% of
More news about: Johnson & Johnson
Dec 09, 2025, 07:30 ET Tec-Dara Combination Offers Substantial Improvement Over Standard Second-Line Therapies for Relapsed or Refractory Multiple Myeloma
researchers noted that strategies for managing infections also improved over the course of the study. Low-grade cytokine release syndrome (CRS) was also common, with grade 1-2 CRS occurring in 60.1% of those receiving Tec-Dara.One limitation of the study is that patients refractory to daratumumab were
More news about: American Society of Hematology
Dec 08, 2025, 08:30 ET Dominari Expands Strategic Leadership with Appointment of Ambassador Jamie McCourt to Advisory Board
all of the principal invested. You can check the background of Dominari Securities and its registered investment professionals and review its SEC Form CRS on FINRA's BrokerCheck site at
More news about: Dominari Holdings Inc.
Dec 07, 2025, 21:08 ET CARsgen Announces Data of Allogeneic BCMA CAR-T Cell Therapy CT0596 for Relapsed/Refractory Multiple Myeloma at the 2025 ASH Annual Meeting
deepening response to VGPR.CT0596 demonstrated a manageable safety profile. Four patients experienced Grade 1 cytokine release syndrome (CRS); no Grade 2 or higher CRS was observed. No immune effector cell-associated neurotoxicity syndrome (ICANS) or graft-versus-host disease (GVHD) was reported. No dose-limiting
More news about: CARsgen Therapeutics